## 10/527679

## ER0809591155

## DT12 Rec'd PCT/PTO 1 1 MAR 2005

ART 34 AMDT

Replacement Sheet

- 24 -

PCT/EP2003/009591

New claims:

- 1. Use of active dendritic cells (DCs) releasing interleukin 12 (IL-12) which are loaded with an antigen against a specific tumor and, due to the treatment with lipopolysaccaride (LPS) and interferon-gamma (IFN- $\gamma$ ), release IL-12, for the preparation of a medicament for treating a patient having said specific tumor.
- 2. Use according to claim 1, characterised in that said treatments is performed after bone marrow transplantation.
- 3. Use according to claim 1 or 2, characterised in that said specific tumor is an advanced malignancy.
- 4. Use according to any one of claims 1 to 3, characterised in that in said DCs are DCs having been taken from the patient having said specific tumor or from the bone marrow donor.
- 5. Use according to any one of claims 1 to 4, characterised in that the DCs have been loaded with an antigen from a tumor cell from said patient having said specific tumor.
- 6. Use according to any one of claims 1 to 5, characterised in that the DCs are additionally charged with a tracer antigen.
- .7. Use according to claim 6, characterised in that said tracer antigen is keyhole limpet hemocyanine (KLH).
- 8. Use according to any one of claims 1 to 7, characterised in that the DCs are additionally charged with an adjuvant, especially with tetanus toxoid.
- 9. Use according to any one of claims 1 to 8, characterised in that the DCs have been generated in vitro from peripheral blood mononuclear cells (PBMCs).
- 10. Composition for triggering IL-12 release from DCs containing LPS, IFN- $\gamma$  and a tumor antigen.
- 11. Composition according to claim 10, characterised in that it

Fmpf >=i+:11/19/2004 11:19



Replacement Sheet

- 24a -

PCT/EP2003/009591

is calf-serum free.

- 12. Use of a combination of LPS, IFN- $\gamma$  and a tumor antigen for triggering IL-12 release from DCs.
- 13. Use according to claim 12, characterised in that the DCs have been loaded with an antigen from a tumor cell from a patient having said tumor.
- 14. Kit for triggering IL-12 release from DCs comprising
- · LPS,
- · IFN-γ and
- a tumor antigen.
- 15. Use of a kit according to claim 14 for triggering IL-12 release from DCs.
- 16. Use according to claim 15, characterised in that the DCs have been loaded with an antigen from a tumor cell from a patient having said tumor.